Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2661503 | 1.00 | CA2 (0.35) | CA2 | |
| SCHEMBL16730248 | 1.00 | CA2 (0.35) | CA2 | |
| SCHEMBL2658122 | 0.83 | PABPC1 (0.31) | CA2 | |
| SCHEMBL17189790 | 0.83 | PABPC1 (0.31) | CA2 | |
| SCHEMBL15690321 | 0.83 | PABPC1 (0.31) | CA2 | |
| SCHEMBL15690638 | 0.83 | PABPC1 (0.31) | CA2 | |
| SCHEMBL15690640 | 0.83 | PABPC1 (0.31) | CA2 | |
| SCHEMBL2658124 | 0.83 | PABPC1 (0.31) | CA2 | |
| SCHEMBL16727652 | 0.73 | CA2 (0.32) | CA2 | |
| SCHEMBL16727647 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3078662-A1 | PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS | Array Biopharma, Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2727910-B1 | Pyridin-2-yl-thiourea and Pyridin-2-yl-amine derivatives as intermediates for the preparation of Pyridin-2yl-amino-1,2,4-thiadiazole glucokinase activators | ARRAY BIOPHARMA INC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-9079890-B2 | Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives | ARRAY BIOPHARMA INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150057448-A1 | INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES | ARRAY BIOPHARMA, INC. | 2015-02-26 | — | — | US | disclosed |
| US-8853409-B2 | Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | ARRAY BIOPHARMA INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2727910-A1 | Pyridin-2-yl-thiourea and Pyridin-2-yl-amine derivatives as intermediates for the preparation of Pyridin-2yl-amino-1,2,4-thiadiazole glucokinase activators | Array Biopharma, Inc. (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2573087-A1 | Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | Array Biopharma, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20120277242-A1 | Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | ARRAY BIOPHARMA, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2209778-B1 | PYRIDIN-2 -YL-AMINO-I, 2, 4 -THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS | ARRAY BIOPHARMA INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8212045-B2 | Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | ARRAY BIOPHARMA, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | ARRAY BIOPHARMA INC. (US) | 2010-08-12 | — | — | US | disclosed |
| EP-2209778-A1 | PYRIDIN-2 -YL-AMINO-I, 2, 4 -THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS | Array Biopharma, Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009042435-A1 | PYRIDIN-2 -YL-AMINO-I, 2, 4 -THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS | ARRAY BIOPHARMA INC. (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277242-A1 | Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | PDXK, GCKR, GCK | CA2 4089/4885 |
| US-20150057448-A1 | INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES | PDXK, IL4I1, CDK2 | CA2 4764/4885 |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | PDXK, GCKR, GCK | CA2 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.